AZN vs INCY
As of Sep 20, 2026, Astrazeneca (AZN) scores 5.0/10 and Incyte (INCY) 7.5/10 on AlphaStocks' five-model composite, so INCY scores higher. AZN trades 14% below its model fair value; INCY trades 36% below its model fair value.
AZN
ASTRAZENECA PLC
5.0
Consider Buy
$166.29
INCY
INCYTE CORP
7.5
Strong Buy
$125.31
AZN vs INCY: Which is the Better Investment?
ASTRAZENECA PLC (AZN) scores 5.0/10 while INCYTE CORP (INCY) scores 7.5/10 on AlphaStocks' composite model. INCYTE CORP has the higher composite rating of Strong Buy. On a P/E basis, INCYTE CORP trades at 19.6x, making it the more attractively priced of the two. INCYTE CORP trades further below its estimated fair value.
This comparison is algorithmically generated and is not financial advice.
| Metric | AZN | INCY |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 5.0/10 | 7.5/10▲ |
| Rating | Consider Buy | Strong Buy▲ |
| Price | $166.29 | $125.31 |
| P/E Ratio | 25.4 | 19.6▲ |
| ROE | 21.9% | 26.0%▲ |
| Market Cap | $260B | $26B |
| Fair Value | $192.63 | $195.21 |
| Dividend Yield | 1.9% | — |
| Sector Rank | #111 of 168 | #3 of 168▲ |
| Model Verdicts | ||
| Piotroski | Strong | Strong |
| Buffett | Strong | Strong |
| Graham | Caution | Neutral▲ |
| Lynch | Neutral | Neutral |
| Greenblatt | Neutral | Attractive▲ |
Related comparisons
AZN vs INCY: Which Stock Scores Higher?
ASTRAZENECA PLC (AZN) and INCYTE CORP (INCY) are both in the Health Care sector. INCY currently leads with a composite score of 7.5/10 (Strong Buy) compared to AZN's 5.0/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer